Altimmune, Inc. (NASDAQ:ALT) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. grew its stake in Altimmune, Inc. (NASDAQ:ALT) by 2.3% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 211,626 shares of the company’s stock after acquiring an additional 4,772 shares during the period. Charles Schwab Investment Management Inc. owned about 0.30% of Altimmune worth $1,299,000 as of its most recent filing with the SEC.

Other large investors have also recently made changes to their positions in the company. Creative Planning lifted its position in shares of Altimmune by 20.5% during the third quarter. Creative Planning now owns 18,411 shares of the company’s stock worth $113,000 after purchasing an additional 3,132 shares in the last quarter. Arizona State Retirement System grew its stake in Altimmune by 34.4% during the 2nd quarter. Arizona State Retirement System now owns 19,847 shares of the company’s stock worth $132,000 after purchasing an additional 5,081 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in Altimmune by 30.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,973 shares of the company’s stock worth $179,000 after purchasing an additional 6,339 shares during the period. Commonwealth Equity Services LLC boosted its stake in shares of Altimmune by 9.0% in the 2nd quarter. Commonwealth Equity Services LLC now owns 87,110 shares of the company’s stock valued at $579,000 after buying an additional 7,165 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in shares of Altimmune by 190.7% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,688 shares of the company’s stock worth $98,000 after buying an additional 9,635 shares in the last quarter. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Price Performance

Altimmune stock opened at $8.40 on Wednesday. The stock’s 50 day moving average price is $7.81 and its 200 day moving average price is $7.08. The company has a market cap of $597.45 million, a PE ratio of -5.42 and a beta of 0.15. Altimmune, Inc. has a 1-year low of $5.28 and a 1-year high of $14.84.

Altimmune (NASDAQ:ALT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The firm had revenue of $0.01 million for the quarter. During the same period in the prior year, the firm posted ($0.39) EPS. On average, equities research analysts anticipate that Altimmune, Inc. will post -1.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on ALT shares. UBS Group began coverage on Altimmune in a research report on Tuesday, November 12th. They set a “buy” rating and a $26.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating and issued a $12.00 price target on shares of Altimmune in a report on Thursday, November 14th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $20.00.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.